Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949425 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04949425 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 3 participants.
The verdict
NCT04949425, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology studies (hereafter referred to as the 'parent studies') who continue to use the therapy
Interventions
- DRUG Adavosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04949425
The ClinicalTrials.gov registry entry for NCT04949425 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adavosertib is the first listed.
NCT04949425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04949425 about?
NCT04949425 is a clinical study titled "A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours". The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology s...
What is the current status of trial NCT04949425?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-09-13. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT04949425?
The interventions under investigation include: Adavosertib (DRUG).
Who is sponsoring clinical trial NCT04949425?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.